44 results on '"Cornel, Jan H."'
Search Results
2. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy
- Author
-
Silvis, Max J.M., Fiolet, Aernoud T.L., Opstal, Tjerk S.J., Dekker, Mirthe, Suquilanda, Daniel, Zivkovic, Minka, Duyvendak, Michiel, The, Salem H.K., Timmers, Leo, Bax, Willem A., Mosterd, Arend, Cornel, Jan H., and de Kleijn, Dominique P.V.
- Published
- 2021
- Full Text
- View/download PDF
3. Electronic health records to facilitate continuous detection of familial hypercholesterolemia
- Author
-
Pepplinkhuizen, Shari, Ibrahim, Shirin, Vink, Rutger, Groot, Bas, Stroes, Erik S.G., Bax, Willem A., and Cornel, Jan H.
- Published
- 2020
- Full Text
- View/download PDF
4. Correlation between septal midwall late gadolinium enhancement on CMR and conduction delay on ECG in patients with nonischemic dilated cardiomyopathy
- Author
-
Becker, Marthe A.J., Allaart, Cornelis P., Zweerink, Alwin, Cornel, Jan H., van de Ven, Peter M., van Rossum, Albert C., and Germans, Tjeerd
- Published
- 2020
- Full Text
- View/download PDF
5. ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial
- Author
-
Ueland, Thor, Åkerblom, Axel, Ghukasyan, Tatevik, Michelsen, Annika E., Becker, Richard C., Bertilsson, Maria, Budaj, Andrzej, Cornel, Jan H., Himmelmann, Anders, James, Stefan K., Siegbahn, Agneta, Storey, Robert F., Kontny, Frederic, Aukrust, Pål, and Wallentin, Lars
- Published
- 2020
- Full Text
- View/download PDF
6. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure: background, aims, and design of RACE II
- Author
-
Van Gelder, Isabelle C., Van Veldhuisen, Dirk J., Crijns, J.G.M., Tuininga, Ype S., Tijssen, Jan G.P., Alings, A. Marco, Bosker, Hans A., Cornel, Jan H., Kamp, Otto, Veeger, Nic J.G.M., Volbeda, Meint, Rienstra, Michiel, Ranchor, Adelita V., TenVergert, Elisabeth M., and Van Den Berg, Maarten P.
- Subjects
Atrial fibrillation -- Care and treatment ,Atrial fibrillation -- Research ,Atrial fibrillation -- Patient outcomes ,Heart beat -- Research ,Health - Published
- 2006
7. Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction
- Author
-
Elhendy, Abdou, Trocino, Giuseppe, Salustri, Alessandro, Cornel, Jan H., Roelandt, Jos R.T.C., Boersma, Eric, Domburg, Ron T. van, Krenning, Eric P., Said, Galal M. El-, and Fioretti, Paolo M.
- Subjects
Heart ventricle, Left ,Echocardiography -- Evaluation ,Radioisotope scanning -- Evaluation ,Health - Published
- 1996
8. Akinesis becoming dykinesis during dobutamine stress echocardiography: a predictor of poor functional recovery after surgical revascularization
- Author
-
Elhendy, Abdou, Cornel, Jan H., Roelandt, Jos R.T.C., Domburg, Ron T. van, and Fioretti, Paolo M.
- Subjects
Coronary heart disease -- Diagnosis ,Tardive dyskinesia -- Causes of -- Diagnosis ,Health ,Diagnosis ,Causes of - Abstract
Background: Akinesis becoming dyskinesis at high-dose dobutamine stress echocardiography (DSE) has been disregarded as a marker of myocardial ischemia. However, to our knowledge, the relationship between this pattern and myocardial [...]
- Published
- 1996
9. Prediction of improvement of ventricular function after first acute myocardial infarction using low-dose dobutamine stress echocardiography
- Author
-
Salustri, Alessandro, Elhendy, Abdou, Garyfallydis, Polyxeny, Ciavatti, Massimo, Cornel, Jan H., Cate, Folkert J. ten, Boersma, Eric, Gemelli, Antonio, Roelandt, Jos R.T.C., and Fioretti, Paolo M.
- Subjects
Heart attack -- Prognosis ,Two-dimensional echocardiography ,Dobutamine ,Heart ventricle, Left -- Physiological aspects ,Heart function tests -- Evaluation ,Health - Abstract
This study was performed to assess the prevalence of spontaneous improvement of regional left ventricular function in patients after acute myocardial infarction, and to evaluate the role of low dose dobutamine stress echocardiography for its prediction. In 57 patients with a first acute myocardial infarction (thrombolysis, n = 27; Q-wave, n = 49), regional wall motion was evaluated with 2 dimensional echocardiography at rest, during a low dose dobutamine stress test performed within 1 week after hospital admission, and at 3-month follow up. Myocardial viability was considered if there was an improvement of [greater than or equal to] grade in dyssynergic segments from rest to low dose dobutamine infusion; recovery of regional function was defined as an improvement of [greater than or equal to] grade between rest and follow-up echocardiograms. Wall motion score index decreased from rest to low dose dobutamine echocardiography (1.46 [+ or -] 0.29 to 1.39 [+ or -] 0.30, p
- Published
- 1994
10. Dobutamine-atropine stress echocardiography and clinical data for predicting late cardiac events in patients with suspected coronary artery disease
- Author
-
Poldermans, Don, Fioretti, Paolo M., Boersma, Eric, Cornel, Jan H., Borst, Filip, Vermeulen, Erik G.J., Arnese, Mariarosaria, Hendy, Abdou El-, and Roelandt, Jos R.T.C.
- Subjects
Echocardiography ,Dobutamine ,Atropine ,Coronary heart disease -- Diagnosis ,Health ,Health care industry - Abstract
PURPOSE: To compare the relative value of clinical variables with dobutamine-atropine stress echocardiography to predict cardiac events during long-term follow-up. Dobutamine stress echocardiography is increasingly used for the detection of coronary artery disease, but little is known of its prognostic value. PATIENTS AND METHODS: A total of 430 patients (310 men; mean age 61 years, range 22 to 90) were enrolled in the study. Patients were referred for chest pain complaints and were unable to perform an adequate exercise stress test. All patients underwent dobutamine-atropine stress test (incremental dobutamine infusion: 10 to 40 [mu]g/kg/minute, continued with atropine 0.25 to 1 mg intravenously if necessary to achieve 85% of the age predicted maximal heart rate, without symptoms or signs of ischemia) and clinical cardiac evaluation. Follow-up was 17 [+ or -] 5 months, with a minimum of 6 months; 3 patients were lost to follow-up. Cardiac events were defined as cardiac death, nonfatal myocardial infarction, and coronary revascularization. RESULTS: Seventy-nine cardiac events occurred in 76 patients: cardiac death (n = 11), nonfatal myocardial infarction (n = 18), and coronary revascularization (n = 50). By multivariate regression analysis, the prognostic value of the stress test in addition to common clinical variables was assessed. (1) Cardiac death was predicted by age greater than 70 years (odds ratio 5.6, 1.5 to 20) or new wall motion abnormalities in a study that is normal at rest (odds ratio 4.1, 1.1 to 15). (2) Death or myocardial infarction was predicted by a history of myocardial infarction (odds ratio 4.8, 1.8 to 13) or age greater than 70 years (odds ratio 2.3, 1.1 to 5.4), and the stress test outcome provided no additional information. (3) If all events were combined, only stress test results were prognostic: new wall motion abnormalities in a study that is normal at rest (odds ratio 3.1, 1.9 to 5.1), wall motion abnormalities at rest (wall motion score at rest [greater than or equal to] 1.12) (odds ratio 2.5, 1.4 to 4.0), or any new wall motion abnormalities during stress (odds ratio 2.0, 1.4 to 3.8). The positive predictive value of any new wall motion abnormality during stress for all late cardiac events was 25% (95% confidence interval [CI] 19 to 31) with a negative predictive value of 87% (95% CI 83 to 91). CONCLUSION: In a large cohort of unselected patients with chest pain syndromes, new wall motion abnormalities induced by dobutamine provide additional information for late cardiac events, independent of clinical variables.
- Published
- 1994
11. Akinesis becoming dyskinesis during high-dose dobutamine stress echocardiography: a marker of myocardial ischemia or a mechanical phenomenon?
- Author
-
Arnese, Mariarosaria, Fioretti, Paolo M., Cornel, Jan H., Postma-Tjoa, Joyce, Reijs, Ambroos E.M., and Roelandt, Jos R.T.C.
- Subjects
Dobutamine -- Physiological aspects ,Echocardiography -- Evaluation ,SPECT imaging -- Evaluation ,Health - Published
- 1994
12. Safety of dobutamine-atropine stress echocardiography in patients with suspected or proven coronary artery disease
- Author
-
Poldermans, Don, Fioretti, Paolo M., Boersma, Eric, Forster, Tamas, Urk, Hero van, Cornel, Jan H., Arnese, Mariarosaria, and Roelandt, Jos R.T.C.
- Subjects
Two-dimensional echocardiography -- Evaluation ,Cardiac patients -- Medical examination ,Health - Abstract
The purpose of this study was to establish the safety of high-dose dobutamine-atropine stress echocardiogrphy in patients with suspected or proven coronary artery disease. Six hundred fifty consecutive examinations were completed. Mean age of patients was 61 years; 300 had a previous myocardial infarction. Heart rate increased from 73 to 129 beats/min during stress testing, blood pressure did not change significantly (from 140/81 to 150/80 mm Hg). Atropine was added to dobutamine in 239 patients when no ischemia was induced with dobutamine alone and the peak heart rate was
- Published
- 1994
13. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man
- Author
-
Wijnands, Giel J.A., Cornel, Jan H., Martea, Magdalena, and Vree, Tom B.
- Subjects
Quinolones -- Physiological aspects -- Analysis ,Drug interactions -- Analysis -- Physiological aspects ,Theophylline -- Analysis -- Physiological aspects ,Health ,Analysis ,Physiological aspects - Abstract
Lomefloxacin (SC-47111) is a recently developed broad-spectrum antibacterial agent, belonging to the fluoroquinolone class. The in vitro activity of lomefloxacin against Gram-positive and Gram-negative bacteria is comparable to the to [...]
- Published
- 1990
14. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
- Author
-
Shavadia, Jay S., Zheng, Yinggan, Green, Jennifer B., Armstrong, Paul W., Westerhout, Cynthia M., McGuire, Darren K., Cornel, Jan H., Holman, Rury R., and Peterson, Eric D.
- Abstract
Background: The effects of β-blocker therapy in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) are unclear. We sought to evaluate associations between β-blocker use in T2D with ASCVD and cardiovascular (CV) outcomes.Methods: In patients with T2D and ASCVD enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), an inverse probability of treatment-weighted Cox proportional hazards model was used to examine the association between baseline β-blocker therapy (at randomization) and the primary CV composite (defined as CV death, non-fatal myocardial infarction [MI], non-fatal stroke, or hospitalization for unstable angina), including in subgroups with prior MI and heart failure (HF); other outcomes evaluated included individual components of the primary composite, hospitalization for HF, and severe hypoglycemic events.Results: Of the 14,671 patients randomized, 9322 (64%) were on a β-blocker at baseline; these patients were more likely to have prior MI or HF. Over a median 3.0 (25th, 75th percentile: 2.2, 3.6) years, the risk of the primary CV composite was significantly higher with baseline β-blocker use versus no β-blocker use (4.5 vs. 3.4 events/100-patient years, adjusted hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.05-1.29); no significant interaction was noted for patients with versus without prior MI or HF. Baseline β-blocker use was not associated with risks for severe hypoglycemic events (HR 1.14, 95% CI 0.88-1.48).Conclusions: In this observational analysis of T2D and ASCVD, baseline β-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic β-blocker therapy in this patient population. (TECOS ClinicalTrials.gov number, NCT00790205). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
- Author
-
Nidorf, Stefan M, Fiolet, Aernoud T. L, Eikelboom, John W, Schut, Astrid, Opstal, Tjerk S. J, Bax, Willem A, Budgeon, Charley A, Tijssen, Jan G. P, Mosterd, Arend, Cornel, Jan H, Thompson, Peter L, and LoDoCo2 Investigators
- Abstract
Because patients with stable coronary artery disease are at continued risk of major atherosclerotic events despite effective secondary prevention strategies, there is a need to continue to develop additional safe, effective and well-tolerated therapies for secondary prevention of cardiovascular disease. RATIONALE AND DESIGN: The LoDoCo (Low Dose Colchicine) pilot trial showed that the anti-inflammatory drug colchicine 0.5 mg once daily appears safe and effective for secondary prevention of cardiovascular disease. Colchicine's low cost and long-term safety suggest that if its efficacy can be confirmed in a rigorous trial, repurposing it for secondary prevention of cardiovascular disease would have the potential to impact the global burden of cardiovascular disease. LoDoCo2 is an investigator-initiated, international, multicentre, double-blind, event driven trial in which 5522 patients with stable coronary artery disease tolerant to colchicine during a 30-day run-in phase have been randomized to colchicine 0.5 mg daily or matching placebo on a background of optimal medical therapy. The study will have 90% power to detect a 30% reduction in the composite primary endpoint: cardiovascular death, myocardial infarction, ischemic stroke and ischemia-driven coronary revascularization. Adverse events potentially related to the use of colchicine will also be collected, including late gastrointestinal intolerance, neuropathy, myopathy, myositis, and neutropenia. CONCLUSION: The LoDoCo2 Trial will provide information on the efficacy and safety of low-dose colchicine for secondary prevention in patients with stable coronary artery disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
- Author
-
Bhatt, Ankeet S., Luo, Nancy, Solomon, Nicole, Pagidipati, Neha J., Ambrosio, Giuseppe, Green, Jennifer B., McGuire, Darren K., Standl, Eberhard, Cornel, Jan H., Halvorsen, Sigrun, Lopes, Renato D., White, Harvey D., Holman, Rury R., Peterson, Eric D., Mentz, Robert J., and TECOS Study Group
- Abstract
International differences in management/outcomes among patients with type 2 diabetes and heart failure (HF) are not well characterized. We sought to evaluate geographic variation in treatment and outcomes among these patients. METHODS AND RESULTS: Among 14,671 participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), those with HF at baseline and a documented ejection fraction (EF) (N = 1591; 10.8%) were categorized by enrollment region (North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific). Cox models were used to examine the association between geographic region and the primary outcome of all-cause mortality (ACM) or hospitalization for HF (hHF) in addition to ACM alone. Analyses were stratified by those with EF <40% or EF ≥40%. The majority of participants with HF were enrolled in Eastern Europe (53%). Overall, 1,267 (79.6%) had EF ≥40%. β-Blocker (83%) and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (86%) use was high across all regions in patients with EF <40%. During a median follow-up of 2.9 years, Eastern European participants had lower rates of ACM/hHF compared with North Americans (adjusted hazard ratio: 0.45; 95% CI: 0.32-0.64). These differences were seen only in the EF ≥40% subgroup and not the EF <40% subgroup. ACM was similar among Eastern European and North American participants (adjusted hazard ratio: 0.79; 95% CI: 0.44-1.45). CONCLUSIONS: Significant variation exists in the clinical features and outcomes of HF patients across regions in TECOS. Patients from Eastern Europe had lower risk-adjusted ACM/hHF than those in North America, driven by those with EF ≥40%. These data may inform the design of future international trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers.
- Author
-
Hoogeveen, Renate M., Opstal, Tjerk S.J., Kaiser, Yannick, Stiekema, Lotte C.A., Kroon, Jeffrey, Knol, Remco J.J., Bax, Willem A., Verberne, Hein J., Cornel, Jan H., and Stroes, Erik S.G.
- Published
- 2019
- Full Text
- View/download PDF
18. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis.
- Author
-
Becker, Marthe A.J., Cornel, Jan H., van de Ven, Peter M., van Rossum, Albert C., Allaart, Cornelis P., and Germans, Tjeerd
- Abstract
Objectives This review and meta-analysis reviews the prognostic value of cardiac magnetic resonance (CMR) in nonischemic dilated cardiomyopathy (DCM). Background Late gadolinium-enhanced (LGE) CMR is a noninvasive method to determine the underlying cause of DCM and previous studies reported the prognostic value of the presence of LGE to identify patients at risk of major adverse cardiovascular events. Methods PubMed was searched for studies describing the prognostic implication of LGE in patients with DCM for the specified endpoints cardiovascular mortality, major ventricular arrhythmic events including appropriate implantable cardioverter-defibrillator therapy, rehospitalization for heart failure, and left ventricular reverse remodeling. Results Data from 34 studies were included, with a total of 4,554 patients. Contrast enhancement was present in 44.8% of DCM patients. Patients with LGE had increased cardiovascular mortality (odds ratio [OR]: 3.40; 95% confidence interval [CI]: 2.04 to 5.67), ventricular arrhythmic events (OR: 4.52; 95% CI: 3.41 to 5.99), and rehospitalization for heart failure (OR: 2.66; 95% CI: 1.67 to 4.24) compared with those without LGE. Moreover, the absence of LGE predicted left ventricular reverse remodeling (OR: 0.15; 95% CI: 0.06 to 0.36). Conclusions The presence of LGE on CMR substantially worsens prognosis for adverse cardiovascular events in DCM patients, and the absence indicates left ventricular reverse remodeling. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
- Author
-
Ducrocq, Gregory, Schulte, Phillip J., Budaj, Andrzej, Cornel, Jan H., Held, Claes, Himmelmann, Anders, Husted, Steen, Storey, Robert F., Cannon, Christopher P., Becker, Richard C., James, Stefan K., Katus, Hugo A., Lopes, Renato D., Sorbets, Emmanuel, Wallentin, Lars, and Steg, Philippe Gabriel
- Abstract
Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit. We sought to compare the relative effects of ischemic and bleeding events on mortality.
Methods: In the PLATelet inhibition and patient Outcomes (PLATO) trial, we compared spontaneous ischemic events (myocardial infarction or stroke) with spontaneous major bleeding events (PLATO major, Thrombolysis In Myocardial Infarction [TIMI] major, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [GUSTO] severe) with respect to risk of mortality using time-dependent Cox proportional hazards models. The comparison was performed using ratio of hazard ratios for mortality increase after ischemic vs bleeding events.Results: A total of 822 patients (4.4%) had ≥1 spontaneous ischemic event; 485 patients (2.6%), ≥1 spontaneous PLATO major bleed, 282 (1.5%), ≥1 spontaneous TIMI major bleed; and 207 (1.1%), ≥1 spontaneous severe GUSTO bleed. In patients who had both events, bleeding occurred first in most patients. Regardless of classification, major bleeding events were associated with increased short- and long-term mortality that were not significantly different from the increase associated with spontaneous ischemic events: ratio of hazard ratios (95% CIs) for short- and long-term mortality after spontaneous ischemic vs bleeding events: 1.46 (0.98-2.19) and 0.92 (0.52-1.62) (PLATO major); 1.26 (0.80-1.96) and 1.19 (0.58-2.24) (TIMI major), 0.72 (0.47-1.10) and 0.83 (0.38-1.79) (GUSTO severe) (all P>0.05) CONCLUSIONS: In patients with ACS on dual antiplatelet therapy, spontaneous major bleeding events seem "prognostically equivalent" to spontaneous ischemic complications. This result allows quantitative comparisons between both actual and predicted bleeding and ischemic risks. Our findings help to better define net clinical benefit of antithrombotic treatments and more accurately estimate mortality after ischemic and bleeding events in patients with ACS. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
20. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
- Author
-
Cornel, Jan H, Tricoci, Pierluigi, Lokhnygina, Yuliya, Moliterno, David J, Wallentin, Lars, Armstrong, Paul W, Aylward, Philip E, Clare, Robert M, Chen, Edmond, Leonardi, Sergio, Van de Werf, Frans, White, Harvey D, Held, Claes, Strony, John, Mahaffey, Kenneth W, and Harrington, Robert A
- Published
- 2015
- Full Text
- View/download PDF
21. Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.
- Author
-
Cornel, Jan H, Lopes, Renato D, James, Stefan, Stevens, Susanna R, Neely, Megan L, Liaw, Danny, Miller, Julie, Mohan, Puneet, Amerena, John, Raev, Dimitar, Huo, Yong, Urina-Triana, Miguel, Gallegos Cazorla, Alex, Vinereanu, Dragos, Fridrich, Viliam, Harrington, Robert A, Wallentin, Lars, Alexander, John H, and APPRAISE-2 Study Group
- Published
- 2015
- Full Text
- View/download PDF
22. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
- Author
-
Brilakis, Emmanouil S., Held, Claes, Meier, Bernhard, Cools, Frank, Claeys, Marc J., Cornel, Jan H., Aylward, Philip, Lewis, Basil S., Weaver, Douglas, Brandrup-Wognsen, Gunnar, Stevens, Susanna R., Himmelmann, Anders, Wallentin, Lars, and James, Stefan K.
- Abstract
Background: Patients with prior coronary artery bypass graft surgery (CABG) who present with an acute coronary syndrome have a high risk for recurrent events. Whether intensive antiplatelet therapy with ticagrelor might be beneficial compared with clopidogrel is unknown. In this substudy of the PLATO trial, we studied the effects of randomized treatment dependent on history of CABG. Methods: Patients participating in PLATO were classified according to whether they had undergone prior CABG. The trial's primary and secondary end points were compared using Cox proportional hazards regression. Results: Of the 18,613 study patients, 1,133 (6.1%) had prior CABG. Prior-CABG patients had more high-risk characteristics at study entry and a 2-fold increase in clinical events during follow-up, but less major bleeding. The primary end point (composite of cardiovascular death, myocardial infarction, and stroke) was reduced to a similar extent by ticagrelor among patients with (19.6% vs 21.4%; adjusted hazard ratio [HR], 0.91 [0.67, 1.24]) and without (9.2% vs 11.0%; adjusted HR, 0.86 [0.77, 0.96]; P
interaction = .73) prior CABG. Major bleeding was similar with ticagrelor versus clopidogrel among patients with (8.1% vs 8.7%; adjusted HR, 0.89 [0.55, 1.47]) and without (11.8% vs 11.4%; HR, 1.08 [0.98, 1.20]; Pinteraction = .46) prior CABG. Conclusions: Prior-CABG patients presenting with acute coronary syndrome are a high-risk cohort for death and recurrent cardiovascular events but have a lower risk for major bleeding. Similar to the results in no-prior-CABG patients, ticagrelor was associated with a reduction in ischemic events without an increase in major bleeding. [Copyright &y& Elsevier]- Published
- 2013
- Full Text
- View/download PDF
23. Effect of coronary artery bypass surgery on myocardial perfusion and ejection fraction response to inotropic stimulation in patients without improvement in resting ejection fraction.
- Author
-
Elhendy, Abdhou, Cornel, Jan H., Elhendy, A, Cornel, J H, van Domburg, R T, Bax, J J, and Roelandt, J R
- Subjects
- *
CORONARY artery bypass , *CORONARY circulation , *CARDIOVASCULAR agents , *PHYSIOLOGY - Abstract
The aim of this study was to assess the effect of coronary artery bypass grafting (CABG) on myocardial perfusion and left ventricular (LV) contractile reserve in patients with reduced ejection fraction (EF). We studied 57 patients (age 59 +/- 8 years, 46 men and 11 women) with EF < or = 40% referred for CABG with dobutamine (up to 40 microg/kg/min) stress-reinjection thallium-201 single-photon emission computed tomography, and radionuclide ventriculography at rest and at low-dose dobutamine before and 3 months after CABG. An increase in resting EF > or = 5% occurred in 12 patients (group A) after CABG (EF 34% before and 46% after CABG), whereas no increase occurred in the remaining 45 patients (group B) (EF 34% before and 32% after CABG). A significant increase in EF from rest to low-dose dobutamine radionuclide ventriculography occurred before and after CABG. The magnitude of increase was more significant after than before CABG in group A (12% vs 7%) as well as in group B (13% vs 7%, both p <0.001). Patients in both groups had a significant reduction in stress, rest, and ischemic perfusion scores after CABG. However, the percentage of reduction in resting perfusion defect score was more significant in group A than in group B (60% vs 30%, respectively, p <0.01). It is concluded that CABG induces a significant improvement in resting myocardial perfusion and EF response to inotropic stimulation, even in the absence of improved EF at rest. Patients without improvement in resting EF after CABG have mild improvement in resting myocardial perfusion that may be sufficient to increase EF after CABG during inotropic stimulation, but not at rest. We describe the myocardium with these characteristics as "the reactive myocardium." [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
24. Impact of severity of coronary stenosis and the collateral circulation on the functional outcome...
- Author
-
Elhendy, Abdou and Cornel, Jan H.
- Subjects
- *
CORONARY artery stenosis , *MYOCARDIAL infarction , *HUMAN abnormalities , *LEFT heart ventricle - Abstract
Assesses the influence of the severity of coronary artery stenosis and collateral circulation after revascularization in patients with myocardial infarction and chronic left ventricular dysfunction. Factors for functional recovery; Absence of correlation between diameter stenosis and viability index.
- Published
- 1997
- Full Text
- View/download PDF
25. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
- Author
-
Povsic, Thomas J., Korjian, Serge, Bahit, M. Cecilia, Chi, Gerald, Duffy, Danielle, Alexander, John H., Vinereanu, Dragos, Tricoci, Pierluigi, Mears, Sojaita Jenny, Deckelbaum, Lawrence I., Bonaca, Marc, Ridker, Paul M., Goodman, Shaun G., Cornel, Jan H., Lewis, Basil S., Parkhomenko, Alexander, Lopes, Renato D., Aylward, Philip, Lincoff, A. Michael, and Heise, Mark
- Subjects
- *
APOLIPOPROTEIN A , *MYOCARDIAL infarction , *ACUTE coronary syndrome - Abstract
The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. This exploratory analysis evaluates the effect of CSL112 therapy on the incidence of cardiovascular (CV) death and recurrent MI. The AEGIS-II trial was an international, multicenter, randomized, double-blind, placebo-controlled trial that randomized 18,219 high-risk acute MI patients to 4 weekly infusions of apoA-I (6 g CSL112) or placebo. The incidence of the composite of CV death and type 1 MI was 11% to 16% lower in the CSL112 group over the study period (HR: 0.84; 95% CI: 0.7-1.0; P = 0.056 at day 90; HR: 0.86; 95% CI: 0.74-0.99; P = 0.048 at day 180; and HR: 0.89; 95% CI: 0.79-1.01; P = 0.07 at day 365). Similarly, the incidence of CV death or any MI was numerically lower in CSL112-treated patients throughout the follow-up period (HR: 0.92; 95% CI: 0.80-1.05 at day 90, HR: 0.89; 95% CI: 0.79-0.996 at day 180, HR: 0.91; 95% CI: 0.83-1.01 at day 365). The effect of CSL112 treatment on MI was predominantly observed for type 1 MI and type 4b (MI due to stent thrombosis). Although CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis–related MI compared with placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these observations. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage...
- Author
-
Clemmensen, Peter, Roe, Matthew T., Hochman, Judith S., Cyr, Derek D., Neely, Megan L., McGuire, Darren K., Cornel, Jan H., Huber, Kurt, Zamoryakhin, Dmitry, White, Harvey D., Armstrong, Paul W., Fox, Keith A.A., Prabhakaran, Dorairaj, Ohman, Erik Magnus, and TRILOGY ACS Investigators
- Abstract
Background: Women with acute coronary syndromes (ACS) are less likely to undergo invasive revascularization than men, but sex-specific differences in long-term outcomes and platelet reactivity among medically managed ACS patients remain uncertain. We examined sex-specific differences in long-term ischemic and bleeding outcomes and platelet reactivity for medically managed ACS patients randomized to prasugrel versus clopidogrel plus aspirin.Methods: Data from 9,326 patients enrolled in TRILOGY ACS were analyzed to determine differences in long-term ischemic and bleeding outcomes between women (n = 3,650 [39%]) and men (n = 5,676 [61%]) randomized to prasugrel 10 mg/d (5 mg/d for patients ≥75 years and/or <60 kg) versus clopidogrel 75 mg/d. Sex-specific differences in 30-day platelet reactivity were analyzed in 2,564 (27%) patients participating in a platelet function substudy.Results: Compared with men, women were older, weighed less, were less likely to have prior myocardial infarction or revascularization, and had lower baseline creatinine clearance and hemoglobin level values. Rates of the composite of cardiovascular death/myocardial infarction/stroke (20.2% vs 19.1%; P = .56), all-cause mortality (12.2% vs 11.7%; P = .88), and Global Use of Strategies to Open Occluded Arteries severe/life-threatening/moderate bleeding (3.8% vs 2.8%; P = .74) through 30 months were similar in women versus men. After adjustment, women had significantly lower risk for ischemic outcomes and all-cause mortality. There were no sex-specific, treatment-related differences in 30-day platelet reactivity.Conclusions: Long-term ischemic and bleeding outcomes in medically managed ACS patients were similar for women versus men, as was treatment-related platelet reactivity. Women had a higher baseline risk profile and, after adjustment, significantly lower risk of the primary composite end point and all-cause death through 30 months. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
27. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial.
- Author
-
Tricoci, Pierluigi, Lokhnygina, Yuliya, Huang, Zhen, Van de Werf, Frans, Cornel, Jan H, Chen, Edmond, Wallentin, Lars, Held, Claes, Aylward, Philip E, Moliterno, David J, Jennings, Lisa K, White, Harvey D, Armstrong, Paul W, Harrington, Robert A, Strony, John, and Mahaffey, Kenneth W
- Published
- 2014
- Full Text
- View/download PDF
28. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.
- Author
-
Bansilal, Sameer, Bonaca, Marc P., Cornel, Jan H., Storey, Robert F., Bhatt, Deepak L., Steg, Ph. Gabriel, Im, Kyungah, Murphy, Sabina A., Angiolillo, Dominick J., Kiss, Robert G., Parkhomenko, Alexander N., Lopez-Sendon, Jose, Isaza, Daniel, Goudev, Assen, Kontny, Frederic, Held, Peter, Jensen, Eva C., Braunwald, Eugene, Sabatine, Marc S., and Oude Ophuis, A.J.
- Subjects
- *
CORONARY disease , *MYOCARDIAL infarction , *HEART diseases , *THROMBOSIS , *BLOOD coagulation - Abstract
Background: Patients with prior myocardial infarction (MI) and multivessel coronary disease (MVD) are at high risk for recurrent coronary events.Objectives: The authors investigated the efficacy and safety of ticagrelor versus placebo in patients with MVD in the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial.Methods: Patients with a history of MI 1 to 3 years before inclusion in the PEGASUS-TIMI 54 trial were stratified in a pre-specified analysis based on the presence of MVD. The effect of ticagrelor (60 mg and 90 mg) on the composite of cardiovascular death, MI, or stroke (major adverse cardiovascular events [MACE]), as well as the composite of coronary death, MI, or stent thrombosis (coronary events), and on TIMI major bleeding, intracranial hemorrhage (ICH), and fatal bleeding were evaluated over a median of 33 months.Results: A total of 12,558 patients (59.4%) had MVD. In the placebo arm, compared with patients without MVD, those with MVD were at higher risk for MACE (9.37% vs. 8.57%, adjusted hazard ratio [HRadj]: 1.24; p = 0.026) and for coronary events (7.67% vs. 5.34%, HRadj: 1.49; p = 0.0005). In patients with MVD, ticagrelor reduced the risk of MACE (7.94% vs. 9.37%, HR: 0.82; p = 0.004) and coronary events (6.02% vs. 7.67%, HR: 0.76; p < 0.0001), including a 36% reduction in coronary death (HR: 0.64; 95% confidence interval: 0.48 to 0.85; p = 0.002). In this subgroup, ticagrelor increased the risk of TIMI major bleeding (2.52% vs. 1.08%, HR: 2.67; p < 0.0001), but not ICH or fatal bleeds.Conclusions: Patients with prior MI and MVD are at increased risk of MACE and coronary events, and experience substantial relative and absolute risk reductions in both outcomes with long-term ticagrelor treatment relative to those without MVD. Ticagrelor increases the risk of TIMI major bleeding, but not ICH or fatal bleeding. For patients with prior MI and MVD, ticagrelor is an effective option for long-term antiplatelet therapy. (Prevention of Cardiovascular Events [e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
29. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
- Author
-
Kotsia, Anna, Brilakis, Emmanouil S., Held, Claes, Cannon, Christopher, Steg, Gabriel P., Meier, Bernhard, Cools, Frank, Claeys, Marc J., Cornel, Jan H., Aylward, Philip, Lewis, Basil S., Weaver, Douglas, Brandrup-Wognsen, Gunnar, Stevens, Susanna R., Himmelmann, Anders, Wallentin, Lars, and James, Stefan K.
- Abstract
Background: Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD. Methods: Patients were classified according to presence of extensive CAD (defined as 3-vessel disease, left main disease, or prior coronary artery bypass graft surgery). The trial's primary and secondary end points were compared using Cox proportional hazards regression. Results: Among 15,388 study patients for whom the extent of CAD was known, 4,646 (30%) had extensive CAD. Patients with extensive CAD had more high-risk characteristics and experienced more clinical events during follow-up. They were less likely to undergo percutaneous coronary intervention (58% vs 79%, P < .001) but more likely to undergo coronary artery bypass graft surgery (16% vs 2%, P < .001). Ticagrelor, compared with clopidogrel, reduced the composite of cardiovascular death, myocardial infarction, and stroke in patients with extensive CAD (14.9% vs 17.6%, hazard ratio [HR] 0.85 [0.73-0.98]) similar to its reduction in those without extensive CAD (6.8% vs 8.0%, HR 0.85 [0.74-0.98], P
interaction = .99). Major bleeding was similar with ticagrelor vs clopidogrel among patients with (25.7% vs 25.5%, HR 1.02 [0.90-1.15]) and without (7.3% vs 6.4%, HR 1.14 [0.98-1.33], Pinteraction = .24) extensive CAD. Conclusions: Patients with extensive CAD have higher rates of recurrent cardiovascular events and bleeding. Ticagrelor reduced ischemic events to a similar extent both in patients with and without extensive CAD, with bleeding rates similar to clopidogrel. [Copyright &y& Elsevier]- Published
- 2014
- Full Text
- View/download PDF
30. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
- Author
-
Cornel, Jan H., Ohman, E. Magnus, Neely, Benjamin, Clemmensen, Peter, Sritara, Piyamitr, Zamoryakhin, Dmitry, Armstrong, Paul W., Prabhakaran, Dorairaj, White, Harvey D., Fox, Keith A.A., Gurbel, Paul A., and Roe, Matthew T.
- Abstract
Background: To further explore the impact of smoking on antiplatelet activity and treatment response, we evaluated time-dependent relationships between smoking status with on-treatment platelet reactivity and clinical outcomes for prasugrel vs. clopidogrel in patients with acute coronary syndromes managed medically without revascularization. Methods and Results: A total of 7062 patients aged <75 years from the primary TRILOGY ACS cohort randomized to prasugrel vs. clopidogrel were evaluated through 30 months by baseline and time-dependent smoking status with adjusted proportional-hazards models. A total of 1613 participants (23%) were included in a platelet function sub-study evaluating serial P2Y
12 reaction unit (PRU) measurements. Current smokers (n = 1566 [22%]) at baseline had fewer comorbidities compared with non-smokers; nearly half quit smoking during follow-up. Although median on-treatment PRU values were lower with prasugrel vs. clopidogrel, persistent smokers had lower serial PRU values in both treatment groups compared with non-smokers, with no differential interaction of treatment response by smoking status. The frequency of cardiovascular death, myocardial infarction, or stroke in current smokers was significantly lower with prasugrel (11.7%) vs. clopidogrel (18.6%), but there was no difference in non-smokers (13.8% vs. 13.7%), with significant interaction between treatment and baseline smoking status (P = .0002). Bleeding events occurred more frequently in prasugrel-treated patients with no significant interaction between treatment and baseline smoking status. Conclusions: Among medically managed ACS patients <75 years of age, the risk of ischemic outcomes was significantly reduced with prasugrel vs. clopidogrel among smokers vs. non-smokers. No interaction between on-treatment platelet reactivity and smoking status was found. [Copyright &y& Elsevier]- Published
- 2014
- Full Text
- View/download PDF
31. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
- Author
-
Cornel, Jan H., Becker, Richard C., Goodman, Shaun G., Husted, Steen, Katus, Hugo, Santoso, Anwar, Steg, Gabriel, Storey, Robert F., Vintila, Marius, Sun, Jie L., Horrow, Jay, Wallentin, Lars, Harrington, Robert, and James, Stefan
- Abstract
Background: Habitual smoking has been associated with increased platelet reactivity, increased risk of thrombotic complications and greater efficacy of clopidogrel therapy over placebo. In the PLATO trial, ticagrelor compared to clopidogrel in patients with acute coronary syndromes (ACS) reduced the primary composite end point of vascular death, myocardial infarction and stroke, without increasing overall rates of major bleeding. We evaluated the results in relation to smoking habits. Methods: Interactions between habitual smokers (n = 6678) and in ex/nonsmokers (n = 11,932) and the effects of randomized treatments on ischemic and bleeding outcomes were evaluated by Cox regression analyses. Results: Habitual smokers had an overall lower risk profile and more often ST-elevation ACS. After adjustment for baseline imbalances, habitual smoking was associated with a higher incidence of definite stent thrombosis (adjusted HR, 1.44 [95% CI, 1.07-1.94]); there were no significant associations with other ischemic or bleeding end points. The effects of ticagrelor compared to clopidogrel were consistent for all outcomes regardless of smoking status. Thus, there was a similar reduction in the primary composite end point for habitual smokers (adjusted HR, 0.83 [95% CI, 0.68-1.00]) and ex/nonsmokers (adjusted HR, 0.89 [95% CI, 0.79-1.00]) (interaction P = .50), and in definite stent thrombosis for habitual smokers (adjusted HR, 0.59 [0.39-0.91]) and ex/nonsmokers (adjusted HR, 0.69 [95% CI, 0.45-1.07]) (interaction P = .61). Conclusions: In patients hospitalized with ACS, habitual smoking is associated with a greater risk of subsequent stent thrombosis. The reduction of vascular death, myocardial infarction, stroke, and stent thrombosis by ticagrelor compared to clopidogrel is consistent regardless of smoking habits. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
32. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR ...
- Author
-
Povsic, Thomas J., Cohen, Mauricio G., Mehran, Roxana, Buller, Christopher E., Bode, Christoph, Cornel, Jan H., Kasprzak, Jarosław D., Montalescot, Gilles, Joseph, Diane, Wargin, William A., Rusconi, Christopher P., Zelenkofske, Steven L., Becker, Richard C., and Alexander, John H.
- Abstract
Anticoagulants are the cornerstone of current acute coronary syndrome (ACS) therapy; however, anticoagulation regimens that aggressively reduce ischemic events are almost uniformly associated with more bleeding. REG1, an anticoagulation system, consists of RB006 (pegnivacogin), an RNA oligonucleotide factor IXa inhibitor, and RB007 (anivamersen), its complementary controlling agent. Phase I and IIa studies defined predictable relationships between doses of RB006, RB007, and degree of antifactor IX activity. The efficacy and safety of REG1 for the treatment of patients with ACS managed invasively and the safety of reversing RB006 with RB007 after cardiac catheterization are unknown. Randomized, partially-blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system compared to unfractionated heparin or low molecular heparin in subjects with acute coronary syndrome (RADAR) is designed to assess both the efficacy of the anticoagulant RB006 and the safety of a range of levels of RB006 reversal with RB007. The objectives of RADAR are (1) to determine the safety of a range of levels of RB006 reversal with RB007 after catheterization, (2) to confirm whether a dose of 1 mg/kg RB006 results in near-complete inhibition of factor IXa in patients with ACS, and (3) to assess the efficacy of RB006 as an anticoagulant in patients with ACS undergoing percutaneous coronary intervention. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
33. Effective predischarge triage at the emergency room with dobutamine stress echocardiography and cardiac troponin T
- Author
-
Bholasingh, Radha, Cornel, Jan H., Kamp, Otto, van Straalen, Jan P., Sanders, Gerard T., Tijssen, Jan G., Umans, Victor A., Visser, Cees A., and de Winter, Robbert J.
- Published
- 2002
- Full Text
- View/download PDF
34. Prognostic value of markers of myocardial damage and inflammation in low to intermediate risk chest pain patients
- Author
-
Bholasingh, Radha, Cornel, Jan H., Kamp, Otto, Windhausen, Alphons, van der Zee, Marc, van Straalen, Jan, Sanders, Gerard T., and de Winter, Robbert J.
- Published
- 2002
- Full Text
- View/download PDF
35. Diagnostic and Therapeutic Usefulness of Coronary Computed Tomography Angiography in Out-Clinic Patients Referred for Chest Pain.
- Author
-
Bom, Michiel J., van der Zee, Petrus M., Cornel, Jan H., van der Zant, Friso M., and Knol, Remco J. J.
- Subjects
- *
CHEST pain diagnosis , *CHEST pain treatment , *COMPUTED tomography , *ANGIOGRAPHY , *TREATMENT effectiveness , *DISEASE management , *CORONARY heart disease complications , *CORONARY heart disease treatment , *ANTILIPEMIC agents , *CHEST pain , *CORONARY artery stenosis , *CORONARY disease , *DIFFERENTIAL diagnosis , *LONGITUDINAL method , *MEDICAL referrals , *RISK assessment , *BODY mass index , *PREDICTIVE tests , *DISEASE incidence , *SEVERITY of illness index , *CORONARY angiography , *DISEASE complications , *THERAPEUTICS - Abstract
Coronary computed tomography angiography (CCTA) is widely used to exclude coronary artery disease (CAD) in patients with low-to-intermediate pretest probability (PTP) of obstructive CAD. The aim of our study was to investigate the reclassification by CCTA and the implications of CCTA results on management because limited studies exist on these subjects; 1,560 patients with chest pain without a history of CAD and with low or intermediate PTP of CAD referred for CCTA from the out-patient clinic were prospectively included. PTP was defined by the Duke Clinical Score as either low (<15%), low-intermediate (15% to 50%), or high-intermediate (50% to 85%). Distribution of CCTA results among the categories of PTP of CAD and the influence of CCTA results on management were analyzed. CCTA revealed obstructive CAD in 7%, 15%, and 23% of cases, in patients with low, low-intermediate, and high-intermediate PTP, respectively; 855 of 1,031 patients (83%) with intermediate PTP of CAD showed no obstructive CAD on CCTA and were consequently reclassified. Management changes after CCTA occurred in 689 patients (44%). In 633 patients (41%), medication was altered and 135 (9%) were referred for invasive coronary angiography. Treatment with statin was initiated in 442 (28%) and stopped in 71 patients (5%). Aspirin was initiated in 192 (12%) and stopped in 139 patients (9%). In conclusion, in a routine clinical cohort, CCTA resulted in reclassification in most patients. Furthermore, our study suggests that the Duke Clinical Score overestimates the probability of obstructive CAD compared with CCTA findings. Finally, CCTA results have implications on patient management, with medication changes in 41% of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Endothelial dysfunction and reduced myocardial perfusion reserve in heart failure secondary to coronary artery disease
- Author
-
de Jong, Richard M., Blanksma, Paul K., Cornel, Jan H., Van den Heuvel, A.d F.M., Siebelink, Hans-Marc J., Vaalburg, Willem, and van Veldhuisen, Dirk J.
- Published
- 2003
- Full Text
- View/download PDF
37. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome.
- Author
-
Opstal, Tjerk S.J., Fiolet, Aernoud T.L., van Broekhoven, Amber, Mosterd, Arend, Eikelboom, John W., Nidorf, Stefan M., Thompson, Peter L., Duyvendak, Michiel, van Eck, J.W. Martijn, van Beek, Eugène A., den Hartog, Frank, Budgeon, Charley A., Bax, Willem A., Tijssen, Jan G.P., El Messaoudi, Saloua, Cornel, Jan H., and LoDoCo2 Trial Investigators
- Subjects
- *
ACUTE coronary syndrome , *CHRONICALLY ill , *COLCHICINE , *SECONDARY prevention , *ISCHEMIC stroke - Abstract
Background: Colchicine reduces risk of cardiovascular events in patients post-myocardial infarction and in patients with chronic coronary disease. It remains unclear whether this effect is related to the time of onset of treatment following an acute coronary syndrome (ACS).Objectives: This study investigates risk for major adverse cardiovascular events in relation to history and timing of prior ACS, to determine whether the benefits of colchicine are consistent independent of prior ACS status.Methods: The LoDoCo2 (Low-Dose Colchicine 2) trial randomly allocated patients with chronic coronary disease to colchicine 0.5 mg once daily or placebo. The rate of the composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization was compared between patients with no prior, recent (6-24 months), remote (2-7 years), or very remote (>7 years) ACS; interaction between ACS status and colchicine treatment effect was assessed.Results: In 5,522 randomized patients, risk of the primary endpoint was independent of prior ACS status. Colchicine consistently reduced the primary endpoint in patients with no prior ACS (incidence: 2.8 vs 3.4 events per 100 person-years; hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.52-1.27), recent ACS (incidence: 2.4 vs 3.3 events per 100 person-years; HR: 0.75; 95% CI: 0.51-1.10), remote ACS (incidence: 1.8 vs 3.2 events per 100 person-years, HR: 0.55; 95% CI: 0.37-0.82), and very remote ACS (incidence: 3.0 vs 4.3 events per 100 person-years, HR: 0.70; 95% CI: 0.51-0.96) (P for interaction = 0.59).Conclusions: The benefits of colchicine are consistent irrespective of history and timing of prior ACS. (The LoDoCo2 Trial: Low Dose Colchicine for secondary prevention of cardiovascular disease [LoDoCo2] ACTRN12614000093684). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
38. Colchicine in Stable Coronary Artery Disease.
- Author
-
Fiolet, Aernoud T.L., Nidorf, Stefan M., Mosterd, Arend, and Cornel, Jan H.
- Abstract
Abstract Purpose Disease management of stable coronary artery disease consists of controlling hemostasis and lipid regulation. No treatment strategies preventing plaque erosion or rupture are yet available. Cholesterol crystal–induced inflammation leading to plaque destabilization is believed to be an important factor contributing to plaque instability and might well be amenable to treatment with anti-inflammatory drugs. Colchicine has anti-inflammatory properties with the potential to address both the direct and indirect inflammatory mechanisms in the plaque. Methods A literature search was performed in MEDLINE (PubMed), EMBASE, and the Cochrane Central Register of Controlled Trials, as well as in the clinical trial registries, to identify finished and ongoing clinical studies on colchicine in stable coronary artery disease. Findings Preclinical findings of colchicine in stable coronary artery disease have shown protective effects on surrogate outcomes, such as myocardial infarction size and postangioplasty restenosis. Retrospective cohort studies in patients with gout report a lower incidence of combined cardiovascular outcomes in those treated with colchicine. Thus far, one prospective, randomized clinical trial has provided evidence on a possible protective effect of colchicine in stable coronary artery disease. Meta-analysis of trials of colchicine in multiple cardiovascular diseases revealed a decrease in myocardial infarction with varying levels of evidence. Currently, 5 major clinical trials involving >10,000 patients are recruiting patients, all focusing on major cardiovascular outcomes. Implications The body and quality of evidence regarding the efficacy of colchicine for secondary prevention of stable and acute phases of coronary artery disease will be greatly expanded in the upcoming years, providing less biased and more accurate effect estimates. If colchicine's anti-inflammatory characteristics translate to improved event-free cardiovascular survival, this relatively safe, low-cost, and well-known drug may become the third pillar (next to lipid regulation and platelet inhibition) in the medical management of stable coronary artery disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
- Author
-
Ridker, Paul M, MacFadyen, Jean G, Glynn, Robert J, Koenig, Wolfgang, Libby, Peter, Everett, Brendan M, Lefkowitz, Martin, Thuren, Tom, and Cornel, Jan H
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *CARDIOVASCULAR disease diagnosis , *CHRONIC kidney failure , *RESEARCH , *MORTALITY , *RESEARCH methodology , *CARDIOVASCULAR diseases , *INTERLEUKIN-1 , *MONOCLONAL antibodies , *EVALUATION research , *MEDICAL cooperation , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials , *BLIND experiment , *STATISTICAL sampling , *LONGITUDINAL method , *CHEMICAL inhibitors ,CARDIOVASCULAR disease related mortality - Abstract
Background: Inflammation contributes to chronic kidney disease (CKD), in part mediated through activation of interleukin (IL)-1β by the NLRP3 inflammasome within the kidney. This process also likely contributes to the accelerated atherosclerosis associated with nephropathy.Objectives: The authors hypothesized that canakinumab, a human monoclonal antibody targeting IL-1β, might reduce cardiovascular event rates and improve renal function among post-myocardial infarction patients with CKD.Methods: Stable post-myocardial infarction patients with high-sensitivity C-reactive protein (hsCRP) ≥ 2mg/l were randomly allocated to placebo or to 1 of 3 doses of canakinumab (50, 150, or 300 mg) given subcutaneously once every 3 months. Participants were followed for incident myocardial infarction, stroke, hospitalization for unstable angina requiring urgent revascularization, cardiovascular death, or death from any cause over a median follow-up period of 3.7 years (maximum 5 years). All patients additionally had serial monitoring of estimated glomerular filtration rate (eGFR), creatinine, the urine albumin to creatinine ratio (uACR), and were monitored for adverse renal and urinary events.Results: Of 10,061 participants, 1,875 (18.6%) had baseline eGFR <60 ml/min/1.73 m2. These moderate CKD patients had higher incidence rates for major adverse vascular events compared with those with eGFR ≥60 ml/min/1.73 m2 (6.92 vs. 4.13 per 100 person-years; p < 0.0001). Random allocation to canakinumab reduced the risk of major adverse cardiovascular events among those with CKD (hazard ratio: 0.82; 95% confidence interval: 0.68 to 1.00; p = 0.05) with the largest cardiovascular benefits accruing among those who achieved on-treatment hsCRP levels below 2 mg/l measured after taking the first dose (hazard ratio: 0.68; 95% confidence interval: 0.53 to 0.86; p = 0.0015). Comparable effects were observed among those with baseline albuminuria or diabetes. Canakinumab had neither clinically meaningful benefits nor substantive harms with respect to serial measures of eGFR, creatinine, the uACR, or reported adverse renal events during trial follow-up.Conclusions: IL-1β inhibition with canakinumab reduces major adverse cardiovascular event rates among high-risk atherosclerosis patients with CKD, particularly among those with a robust anti-inflammatory response to initial treatment. These cardiovascular benefits accrued with no adverse clinical renal events. (Canakinumab Anti-inflammatory Thrombosis Outcomes Study [CANTOS]; NCT01327846). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
40. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.
- Author
-
Vranckx, Pascal, White, Harvey D., Huang, Zhen, Mahaffey, Kenneth W., Armstrong, Paul W., Van de Werf, Frans, Moliterno, David J., Wallentin, Lars, Held, Claes, Aylward, Philip E., Cornel, Jan H., Bode, Christoph, Huber, Kurt, Nicolau, José C., Ruzyllo, Witold, Harrington, Robert A., and Tricoci, Pierluigi
- Subjects
- *
ACUTE coronary syndrome , *HEMORRHAGE , *CLINICAL trials , *PATIENTS , *PROGNOSIS , *DISEASE risk factors , *STROKE prevention , *MYOCARDIAL infarction , *COMPARATIVE studies , *CORONARY artery bypass , *RESEARCH methodology , *MEDICAL cooperation , *ORGANIC compounds , *PYRIDINE , *RESEARCH , *RISK assessment , *SURGICAL stents , *EVALUATION research , *RANDOMIZED controlled trials , *BLIND experiment , *SEVERITY of illness index , *PLATELET aggregation inhibitors , *PREVENTION ,CARDIOVASCULAR disease related mortality - Abstract
Background: The Bleeding Academic Research Consortium (BARC) scale has been proposed to standardize bleeding endpoint definitions and reporting in cardiovascular trials. Validation in large cohorts of patients is needed.Objectives: This study sought to investigate the relationship between BARC-classified bleeding and mortality and compared its prognostic value against 2 validated bleeding scales: TIMI (Thrombolysis In Myocardial Infarction) and GUSTO (Global Use of Strategies to Open Occluded Arteries).Methods: We analyzed bleeding in 12,944 patients with acute coronary syndromes without ST-segment elevation, with or without early invasive strategy. The main outcome measure was all-cause death.Results: During follow-up (median: 502 days), noncoronary artery bypass graft (CABG) bleeding occurred in 1,998 (15.4%) patients according to BARC (grades 2, 3, or 5), 484 (3.7%) patients according to TIMI minor/major, and 514 (4.0%) patients according to GUSTO moderate/severe criteria. CABG-related bleeding (BARC 4) occurred in 155 (1.2%) patients. Patients with BARC (2, 3, or 4) bleeding had a significant increase in risk of death versus patients without bleeding (BARC 0 or 1); the hazard was highest in the 30 days after bleeding (hazard ratio: 7.35; 95% confidence interval: 5.59 to 9.68; p < 0.0001) and remained significant up to 1 year. The hazard of mortality increased progressively with non-CABG BARC grades. BARC 4 bleeds were significantly associated with mortality within 30 days (hazard ratio: 10.05; 95% confidence interval: 5.41 to 18.69; p < 0.0001), but not thereafter. Inclusion of BARC (2, 3, or 4) bleeding in the 1-year mortality model with baseline characteristics improved it to an extent comparable to TIMI minor/major and GUSTO moderate/severe bleeding.Conclusions: In patients with acute coronary syndromes without ST-segment elevation, bleeding assessed with the BARC scale was significantly associated with risk of subsequent death up to 1 year after the event and risk of mortality increased gradually with higher BARC grades. Our results support adoption of the BARC bleeding scale in ACS clinical trials. (Trial to Assess the Effects of Vorapaxar [SCH 530348; MK-5348] in Preventing Heart Attack and Stroke in Participants With Acute Coronary Syndrome [TRACER] [Study P04736]; NCT00527943). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
41. Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin: A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
- Author
-
Cleland, John G.F., McMurray, John J.V., Kjekshus, John, Cornel, Jan H., Dunselman, Peter, Fonseca, Cândida, Hjalmarson, Åke, Korewicki, Jerzy, Lindberg, Magnus, Ranjith, Naresh, van Veldhuisen, Dirk J., Waagstein, Finn, Wedel, Hans, and Wikstrand, John
- Subjects
- *
CHRONIC kidney failure , *HEART failure patients , *CARDIOVASCULAR agents , *CORONARY disease , *PLACEBOS , *MYOCARDIAL infarction , *RANDOMIZED controlled trials , *PATIENTS - Abstract
Objectives: We investigated whether plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP), a marker of cardiac dysfunction and prognosis measured in CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure), could be used to identify the severity of heart failure at which statins become ineffective. Background: Statins reduce cardiovascular morbidity and mortality in many patients with ischemic heart disease but not, overall, those with heart failure. There must be a transition point at which treatment with a statin becomes futile. Methods: In CORONA, patients with heart failure, reduced left ventricular ejection fraction, and ischemic heart disease were randomly assigned to 10 mg/day rosuvastatin or placebo. The primary composite outcome was cardiovascular death, nonfatal myocardial infarction, or stroke. Results: Of 5,011 patients enrolled, NT-proBNP was measured in 3,664 (73%). The midtertile included values between 103 pmol/l (868 pg/ml) and 277 pmol/l (2,348 pg/ml). Log NT-proBNP was the strongest predictor (per log unit) of every outcome assessed but was strongest for death from worsening heart failure (hazard ratio [HR]: 1.99; 95% confidence interval [CI]: 1.71 to 2.30), was weaker for sudden death (HR: 1.69; 95% CI: 1.52 to 1.88), and was weakest for atherothrombotic events (HR: 1.24; 95% CI: 1.10 to 1.40). Patients in the lowest tertile of NT-proBNP had the best prognosis and, if assigned to rosuvastatin rather than placebo, had a greater reduction in the primary end point (HR: 0.65; 95% CI: 0.47 to 0.88) than patients in the other tertiles (heterogeneity test, p = 0.0192). This reflected fewer atherothrombotic events and sudden deaths with rosuvastatin. Conclusions: Patients with heart failure due to ischemic heart disease who have NT-proBNP values <103 pmol/l (868 pg/ml) may benefit from rosuvastatin. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
42. Percutaneous Coronary Intervention With Off-Site Cardiac Surgery Backup for Acute Myocardial Infarction as a Strategy to Reduce Door-to-Balloon Time
- Author
-
Peels, Hans O., de Swart, Hans, Ploeg, Tjeerd v.d., Hautvast, Raymond W., Cornel, Jan H., Arnold, Alf E., Wharton, Thomas P., and Umans, Victor A.
- Subjects
- *
CARDIAC surgery , *MYOCARDIAL infarction , *CLINICAL competence , *CARDIOLOGY - Abstract
We investigated whether primary percutaneous coronary intervention (PCI) for patients admitted with an acute ST-segment elevation myocardial infarction could be performed more rapidly and with comparable outcomes in a community hospital versus a tertiary center with cardiac surgery. We started the first PCI with an off-site surgery program in The Netherlands in 2002 and report the results of 439 consecutive patients. In the safety phase, 199 patients presenting with ST-segment elevation myocardial infarction were randomly assigned to treatment at our off-site center versus a more distant cardiac surgery center. In the confirmation phase, 240 consecutive patients were treated in the off-site hospital. Safety and efficacy end points were the rate of an angiographically successful PCI procedure (diameter stenosis <50% and Thrombolysis In Myocardial Infarction grade 3 flow) in the absence of major adverse cardiac and cerebrovascular events at 30 days. The randomization phase showed a 37-minute decrease in door-to-balloon time (p <0.001) with comparable procedural and clinical successes (91% Thrombolysis In Myocardial Infarction grade 3 flow in the 2 groups). In the confirmation phase, the 30-day rate without major adverse cardiac and cerebrovascular events was 95%. None of the 439 patients in the study required emergency surgery for failed primary PCI. In conclusion, time to treatment with primary PCI can be significantly shortened when treating patients in a community hospital setting with off-site cardiac surgery backup compared with transport for PCI to a referral center with on-site surgery. PCI at hospitals with off-site cardiac surgery backup can be considered a needed strategy to improve access to primary PCI for a larger segment of the population and can be delivered with a very favorable safety profile. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
43. Safety and efficacy of a nurse-led clinic for post-operative coronary artery bypass grafting patients
- Author
-
Broers, Carla, Hogeling-Koopman, Jeanne, Burgersdijk, Cees, Cornel, Jan H., van der Ploeg, J., and Umans, Victor A.
- Subjects
- *
CORONARY arteries , *HEART blood-vessels , *MYOCARDIAL revascularization ,CARDIAC surgery patients - Abstract
Abstract: Background: New opportunities are emerging for nurses as sovereign health care specialists. In accordance with British and American experience, several universities on the European Continent started Advance Nursing Practice programs for nurses to become certified nurse specialists, functioning as intermediates between the consultant, the ward nurse and the patient. Aims: This observational study was conducted to evaluate safety and efficacy of a nurse-led clinic for patients recovering after a successful coronary artery bypass grafting operation. Methods: From April 1999 to June 2002, 584 consecutive patients underwent a coronary artery bypass graft operation after which they were admitted to the cardiology ward. Subsequently, these patients were treated either by a certified nurse practitioner or by a resident. Both were supervised by an attending cardiologist. The study elapses three time phases: phase I (1999) first control period, phase II (2000–2002) the nurse practitioner was in charge, and phase III (2002) the second control period. Results: A total of 584 patients were admitted at a mean of 5.5 and 6.3 days after the operation (phase II vs I+III, respectively). Typically these patients were men (79%) with a mean age of 67±11 years. During the observation period, 349 patients were treated by the nurse practitioner and 235 by a resident (89 in phase I and 146 in phase III). Two patients suddenly died while admitted. All other patients recovered and were discharged. The nurse-treated patients (phase II) were discharged significantly sooner than those treated by the regular staff (11.5 vs 14.7 days; p <0.001, respectively). The 30-day mortality rate was 0.4% and did not differ between the respective patient or time-phase groups. Conclusion: A nurse-led clinic for patients recovering from a coronary artery bypass graft operation was safely and efficaciously introduced in a large Dutch non-cardiac surgery hospital. This study protocol may serve as a preamble for upcoming nurse-led programs to developed and implement the sovereign care by nurse practitioners for various diseases and in different settings. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
44. CONSISTENT EFFICACY OF COLCHICINE OVER TIME IN PATIENTS WITH RECENT VERSUS REMOTE PRIOR ACUTE CORONARY SYNDROME - A LODOCO2 SUBSTUDY.
- Author
-
Opstal, Tjerk, Fiolet, Aernoud T.L., Mosterd, Arend, Eikelboom, John, Nidorf, Stefan, Thompson, Peter, Budgeon, Charley, Tijssen, Jan, El Messaoudi, Saloua, and Cornel, Jan H.
- Subjects
- *
ACUTE coronary syndrome , *COLCHICINE - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.